Muruganantham Bharathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muruganantham Bharathi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Abdullah A. Alarfaj
Department of Botany and Microbiology, College of Science King Saud University Riyadh Saudi Arabia
1 shared publicationAbdurahman Hajinur Hirad
Department of Botany and Microbiology, College of Science King Saud University Riyadh Saudi Arabia
1 shared publication- Indumathi Thangavelu
Department of Chemistry, CHRIST (Deemed to be University), Bangalore, India
1 shared publication Jagadeesh Suriyaprakash
Guangdong Provincial Key Laboratory of Nanophotonic Functional Materials and Devices, School of Information and Optoelectronic Science and Engineering South China Normal University Guangzhou China
1 shared publicationPalanisamy Arulselvan
Department of Chemistry, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS) Saveetha University Chennai Tamil Nadu India
1 shared publicationRajeswari Ravindran
Preclinical Department, Faculty of Medicine Universiti Kuala Lumpur Royal College of Medicine Perak (UniKL‐RCMP) Ipoh Perak Malaysia
1 shared publication
Latest Publications
- 3 November 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (3) , 683-694
Carboplatin‐loaded zeolitic imidazolate framework‐8: Induction of antiproliferative activity and apoptosis in breast cancer cell
The challenge with breast cancer is its ongoing high prevalence and difficulties in early detection and access to effective care. A solution lies in creating tailored metal–organic frameworks to encapsulate anticancer drugs, enabling precise and targeted treatment with less adverse effects and improved effectiveness. Zeolitic imidazolate framework‐8 (ZIF‐8) and carboplatin (CP)‐loaded ZIF‐8 were synthesized and characterized using various analytical techniques. High Resolution‐transmission electron microscopy of ZIF‐8 and CP@ZIF‐8 indicates that the particles had a spherical shape and were nanosized. The drug release rate of CP is 98% under an acidic medium (pH 5.5) because of the dissolution of ZIF‐8 into its coordinating ions, whereas 35% in a physiological medium (pH 7.4) with the addition of CP, the high porosity, and pore diameter of ZIF‐8 decrease from 1243 to 1041 m2/g. Breast cancer MCF‐7 cells were shown greater IC50 in CP@ZIF‐8 (15.01 ± 3.03 µg/mL) than free CP (34.98 ± 4.25 µg/mL) in an in vitro cytotoxicity assessment. The cytotoxicity of the CP@ZIF‐8 against MCF‐7 cells was studied using the methylthiazolyldiphenyl‐tetrazolium bromide method. The morphological changes were examined using fluorescent staining (acridine orange–ethidium bromide and Hoechst 33258) methods. The comet assay assessed the DNA fragmentation (single‐cell gel electrophoresis). The results from the study revealed that CP@ZIF‐8 can be used in the treatment of breast cancer.
- 3 November 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (3) , 683-694
Carboplatin‐loaded zeolitic imidazolate framework‐8: Induction of antiproliferative activity and apoptosis in breast cancer cell
The challenge with breast cancer is its ongoing high prevalence and difficulties in early detection and access to effective care. A solution lies in creating tailored metal–organic frameworks to encapsulate anticancer drugs, enabling precise and targeted treatment with less adverse effects and improved effectiveness. Zeolitic imidazolate framework‐8 (ZIF‐8) and carboplatin (CP)‐loaded ZIF‐8 were synthesized and characterized using various analytical techniques. High Resolution‐transmission electron microscopy of ZIF‐8 and CP@ZIF‐8 indicates that the particles had a spherical shape and were nanosized. The drug release rate of CP is 98% under an acidic medium (pH 5.5) because of the dissolution of ZIF‐8 into its coordinating ions, whereas 35% in a physiological medium (pH 7.4) with the addition of CP, the high porosity, and pore diameter of ZIF‐8 decrease from 1243 to 1041 m2/g. Breast cancer MCF‐7 cells were shown greater IC50 in CP@ZIF‐8 (15.01 ± 3.03 µg/mL) than free CP (34.98 ± 4.25 µg/mL) in an in vitro cytotoxicity assessment. The cytotoxicity of the CP@ZIF‐8 against MCF‐7 cells was studied using the methylthiazolyldiphenyl‐tetrazolium bromide method. The morphological changes were examined using fluorescent staining (acridine orange–ethidium bromide and Hoechst 33258) methods. The comet assay assessed the DNA fragmentation (single‐cell gel electrophoresis). The results from the study revealed that CP@ZIF‐8 can be used in the treatment of breast cancer.